Medication info
Neurotan Plus F Tablets

Neurotan Plus F Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Korea Union Pharmaceutical Co., Ltd.
Appearance
Light yellow oval film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200607908 · Notified 2006.09.13 · Insurance code 665500280

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect is generally achieved approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or greater. Administration is not recommended in patients with more severe renal impairment, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in these patients because this medicine cannot provide the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment.
Child dose
Under 18 years of age: Since there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Korea Union Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension who do not achieve sufficient blood pressure control with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect is generally achieved approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or greater. Administration is not recommended in patients with more severe renal impairment, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in these patients because this medicine cannot provide the initial losartan potassium dose of 25 mg required for patients with hepatic impairment who need dose adjustment.

Child dose

Under 18 years of age: Since there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication may cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Patients with known allergies to any ingredients included in this drug or to the drug itself, patients with severely impaired renal function, patients with severe hepatic impairment, and women who are pregnant or may become pregnant should not take this medication. Patients with excessively low blood pressure or electrolyte imbalance, those with liver or kidney disease, patients with hyperuricemia or gout, and the elderly should use caution when taking this medication. Due to the hydrochlorothiazide component, the concentration of electrolytes in the body may change, so regular blood tests should be performed to monitor electrolyte status, and extra caution is needed in cases of dehydration, vomiting, or diarrhea. This medication lowers blood pressure, so dizziness or drowsiness may occur at the beginning of treatment or with dosage adjustments; care should be taken when driving or operating machinery. Do not arbitrarily take potassium supplements or medications containing potassium, and it is essential to consult with a doctor or pharmacist due to potential drug interactions with other medications being taken. If allergic symptoms such as rash, swelling, or difficulty breathing occur during use, discontinue use immediately and inform medical personnel. This medication has not been shown to be safe for children, so it is not used in pediatric or adolescent patients. Store this medication out of reach of children, keeping it sealed in its original container.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 156 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina pectoris
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • reduced libido
  • memory impairment
  • migraine
  • neuropathy
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbance
  • drowsiness
  • tremors
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous obstruction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • mucocutaneous syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythematous skin
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis
  • hypotension
  • tachycardia
  • hypokalemia
  • hypochloremia
  • hyponatremia
  • thirst
  • thirst
  • somnolence
  • drowsiness
  • restlessness
  • seizures
  • myalgia
  • muscle fatigue
  • decreased urine output
  • tachycardia
  • nausea
  • vomiting
  • foamy urine
  • arrhythmia
  • acute respiratory distress syndrome
  • elevated serum creatinine
  • angioedema
  • vasculitis
  • thrombocytopenia
  • angioedema
  • vasculitis
  • thrombocytopenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a container that does not allow light or air to enter, stored at room temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain its efficacy for a longer time.

Appearance and packaging

Appearance

Light yellow oval film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.